Latest

• HTA and public coverage of new mental health drugs in Quebec and Canada.

  INESSS v CDR and RAMQ v ROC »

• Medical Resources in Canada and OECD countries. 2019 Edition.

  Canada’s health system supplies patients with fewer medical resources than the health systems of most OECD countries. »

• Evidence that innovative medicines improve health and economic outcomes: focused literature review.

  There is abundant empirical evidence that pharmaceutical innovation improves population-level health outcomes and societal-level net economic benefits. »

• Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options.

  Study weighs the options being considered by the federal Advisory Council on the Implementation of National Pharmacare. »

• Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018.

  The pCPA should demonstrate to Canadians that its negotiations to contain the costs of new drugs are not limiting patients’ access to innovative drugs. »

• Facts about the cost of patented drugs in Canada: 2018 Edition.

  Policymakers are not fully informed about pharmaceutical costs - particularly regarding patented medicines. »

• Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?

  National Pharmacare advocates claim that out-of-pocket costs for prescription drugs are forcing people to trade-off food, heat and rent versus medicines. Is it true? »

• New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making

  This case study demonstrates that the proposed changes in the PMPRB’s guidelines will create a high level of uncertainty among manufacturers of drugs for rare disorders. »

• Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate

  Study suggests PBO underestimated the cost of National Pharmacare; adjusting the gaps in existing public drug plans would be less expensive for taxpayers. »